| scholarly article | Q13442814 |
| P50 | author | Elizabeth Jaffee | Q29452184 |
| Lei Zheng | Q59833013 | ||
| P2093 | author name string | Eric R Lutz | |
| Heather Kinkead | |||
| P2860 | cites work | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| Characteristics of tertiary lymphoid structures in primary cancers | Q27012852 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Cancer statistics, 2014 | Q27861018 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation | Q28141319 | ||
| Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy | Q29617774 | ||
| Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape | Q29620881 | ||
| Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation | Q33848077 | ||
| Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation | Q33887648 | ||
| Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer | Q34362516 | ||
| A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation | Q34904065 | ||
| Unique ectopic lymph node-like structures present in human primary colorectal carcinoma are identified by immune gene array profiling | Q35070183 | ||
| Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma | Q36810574 | ||
| 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? | Q41883987 | ||
| Development and characterization of a cytokine-secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials. | Q42818041 | ||
| Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. | Q43785551 | ||
| Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma | Q56899396 | ||
| Long-Term Survival for Patients With Non–Small-Cell Lung Cancer With Intratumoral Lymphoid Structures | Q56965922 | ||
| P433 | issue | 11 | |
| P921 | main subject | pancreatic cancer | Q212961 |
| immunotherapy | Q1427096 | ||
| P304 | page(s) | e962401 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | OncoImmunology | Q18026500 |
| P1476 | title | Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy | |
| P478 | volume | 3 |
| Q37265792 | Actionable Intelligence Provided by Pancreatic Cancer Genomic Landscape: Are Targets for Curative Therapy On The Map? |
| Q33753714 | Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma |
| Q48290538 | Clinical evaluation of macrophages in cancer: role in treatment, modulation and challenges. |
| Q60922811 | Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle |
| Q38787052 | Considerations for the combination of anticancer vaccines and immune checkpoint inhibitors. |
| Q26768252 | Dendritic cell-based vaccine for pancreatic cancer in Japan |
| Q26778793 | Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors |
| Q56890107 | Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options |
| Q61448030 | Pancreatic cancer microenvironment: a current dilemma |
| Q30250026 | Pancreatic cancer: yesterday, today and tomorrow. |
| Q90749121 | Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects |
| Q47701712 | Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer |
| Q53850924 | Rekindling cancer vaccines. |
| Q88318271 | The Immune Revolution: A Case for Priming, Not Checkpoint |
| Q64113812 | Therapeutic challenges and current immunomodulatory strategies in targeting the immunosuppressive pancreatic tumor microenvironment |
| Q92173942 | Tumour microenvironment of pancreatic cancer: immune landscape is dictated by molecular and histopathological features |
Search more.